Pancreatic cancer cells react to CDK4/6 inhibition with enhanced oxidative phosphorylation, associated with an RB-dependent increase in mitochondrial mass and mTORC1 activation (41). The gene discussed is CDK4; the disease is familial pancreatic carcinoma.